Acrivon buys Aqilion's oral JAK1 drug, taking oncology biotech beyond cancer
The US company has acquired a selective JAK1 inhibitor and a preclinical PKCθ project from Aqilion, with no further payments due to the Swedish seller.
Acrivon Therapeutics, a US biotech focused on oncology, has bought an oral JAK1 inhibitor from Sweden's Aqilion AB, giving it a first foothold outside cancer. The company announced the purchase on 6 November 2026. The drug, now called ACR-525, was previously known as AQ280. A preclinical programme aimed at PKCθ is part of the package.
The commercial structure is the main thing to note. Acrivon did not say how much cash it paid. It did say Aqilion will receive no royalties or milestone payments later. Acrivon also struck a separate agreement ending earlier royalty and milestone obligations tied to the asset and owed to LEO Pharma. Its terms were not given. On the information released, no downstream payments to either party are disclosed.
Acrivon plans to go after eosinophilic esophagitis first with ACR-525, and sees inflammatory bowel disease as a later opportunity. The company has not set out trial design, timelines or filing plans. Any eventual launch in eosinophilic esophagitis would be judged against therapies already available to patients.
Acrivon has scheduled a key opinion leader webcast for 10 November 2026. It is the next likely occasion for the company to say more about its immunology strategy.
Why it matters
- Acrivon is using an asset purchase to diversify from oncology into immunology, but has shared no development timetable or financial forecasts.
- With the price undisclosed and no later payments owed to Aqilion or LEO Pharma, the asset's economics cannot be assessed from public information, though its ownership position looks uncomplicated.
- Eosinophilic esophagitis is the lead target, so ACR-525 would eventually have to compete with existing treatments.
- The 10 November webcast is the next checkpoint for clinical and strategic detail.
Company's press release (SEC filing): Acrivon Therapeutics, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
MacroGenics reports $288M cash and 2028 runway, putting B7-H3 ADC MGC026 in head and neck cancer first
Xenetic reports Q3 loss, advances all-stock Santersus deal and doses first DNase I CAR-T patient
Longeveron seeks FDA meeting after ELPIS II miss and starts strategic alternatives review
Silence Therapeutics narrows Q3 loss as Merck KGaA deal and divesiran data take centre stage
Theriva Sells SYN-004 Antibiotic-Enzyme Assets to Biossil Labs for $350,000 Upfront
